TY - JOUR
T1 - Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer
AU - Gibbs, Lee D.
AU - Vishwanatha, Jamboor K.
N1 - Funding Information:
Research reported in this publication was supported by of the National Institutes of Health under the National Cancer Institute Award Number R01CA220273 and National Institute on Minority Health And Health Disparities Award Number P20MD006882. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© Gibbs et al.
PY - 2018
Y1 - 2018
N2 - Objective: Previous studies have shown Annexin A1 (AnxA1) and Annexin A2 (AnxA2) association with the aggressive behavior of Triple Negative Breast Cancer (TNBC). Our aim was to determine the correlation of AnxA1 and AnxA2 with poor prognosis of TNBC patients. Methods: We analyzed the gene expression of the human annexin family from microarray datasets and correlated with clinical outcomes to determine their ability to predict prognosis. Results: Within a mean follow-up time of 57.2 months in our TNBC cohort, high AnxA1 expression was an independent indicator of poor overall survival (OS) [hazard ratio (HR), 2.14; 95% confidence interval (CI), 1.22-3.78] and relapse-free survival (RFS) prognosis [HR, 1.66; 95% CI, 1.28-2.17]. Additionally, high AnxA2 expression was an independent indicator of poor OS [HR, 2.66; 95% CI, 1.14-6.25], RFS [HR, 1.45; 95% CI, 1.12-1.89], RFS [HR, 1.45; 95% CI, 1.12-1.89), and distant metastasis free survival (DMFS) prognosis [HR, 1.5; 95% CI, 1.16-1.95]. Analyses of TNBC patients with both high AnxA1 and AnxA2, demonstrates a significant decrease in OS (P=0.0017) and RFS (P=0.0002) when compared to the expression of genes independently. Furthermore, AnxA1 prognostic impact relies on high AnxA2 expression and both are preferential for TNBC when compared to other breast cancer subtypes. Conclusion: Together these findings indicate that AnxA1 and AnxA2 are preferential dual prognostic predictors among TNBC patients.
AB - Objective: Previous studies have shown Annexin A1 (AnxA1) and Annexin A2 (AnxA2) association with the aggressive behavior of Triple Negative Breast Cancer (TNBC). Our aim was to determine the correlation of AnxA1 and AnxA2 with poor prognosis of TNBC patients. Methods: We analyzed the gene expression of the human annexin family from microarray datasets and correlated with clinical outcomes to determine their ability to predict prognosis. Results: Within a mean follow-up time of 57.2 months in our TNBC cohort, high AnxA1 expression was an independent indicator of poor overall survival (OS) [hazard ratio (HR), 2.14; 95% confidence interval (CI), 1.22-3.78] and relapse-free survival (RFS) prognosis [HR, 1.66; 95% CI, 1.28-2.17]. Additionally, high AnxA2 expression was an independent indicator of poor OS [HR, 2.66; 95% CI, 1.14-6.25], RFS [HR, 1.45; 95% CI, 1.12-1.89], RFS [HR, 1.45; 95% CI, 1.12-1.89), and distant metastasis free survival (DMFS) prognosis [HR, 1.5; 95% CI, 1.16-1.95]. Analyses of TNBC patients with both high AnxA1 and AnxA2, demonstrates a significant decrease in OS (P=0.0017) and RFS (P=0.0002) when compared to the expression of genes independently. Furthermore, AnxA1 prognostic impact relies on high AnxA2 expression and both are preferential for TNBC when compared to other breast cancer subtypes. Conclusion: Together these findings indicate that AnxA1 and AnxA2 are preferential dual prognostic predictors among TNBC patients.
KW - Annexin
KW - Prognosis
KW - Relapse
KW - Survival
KW - Triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85039996292&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.23627
DO - 10.18632/oncotarget.23627
M3 - Article
AN - SCOPUS:85039996292
SN - 1949-2553
VL - 9
SP - 2697
EP - 2704
JO - Oncotarget
JF - Oncotarget
IS - 2
ER -